Synthetic Biology Market: The Fastest Growing Sector in Biotechnology?

Introduction

The synthetic biology market is characterized by the presence of a diverse group of biotechnology, life sciences, industrial enzyme, and advanced materials companies that are driving innovation across healthcare, agriculture, industrial biotechnology, biofuels, specialty chemicals, and genomics applications. Market participants are focused on developing cutting-edge technologies such as gene editing, synthetic DNA and RNA synthesis, industrial fermentation, enzyme engineering, cell and gene therapies, bio-based chemicals, and sustainable manufacturing solutions. Leading companies leverage proprietary platforms, artificial intelligence, machine learning, automation, and advanced bioengineering capabilities to accelerate product development and commercialization. With growing demand for sustainable alternatives, precision medicine, and next-generation biological solutions, key industry players continue to expand their global presence through research and development investments, strategic partnerships, technology advancements, and diversified product portfolios. These initiatives are strengthening the competitive landscape and supporting the continued growth of the synthetic biology market across both developed and emerging economies.

Global Synthetic biology Market 2025, Revenue and Market share analysis:

The global synthetic biology market was valued between approximately US$ 17 billion and US$ 22.3 billion in 2025 and is experiencing rapid growth due to significant advancements in gene editing technologies, DNA synthesis, genome engineering, and the increasing adoption of biologically engineered solutions across healthcare, agriculture, industrial biotechnology, and environmental applications. The market is projected to expand at a strong compound annual growth rate (CAGR) of approximately 17% to 26% over the next decade, reflecting growing investments in biotechnology innovation and sustainable manufacturing. Market forecasts vary among research organizations, with estimates suggesting that the industry could reach between US$ 69 billion and US$ 137 billion by the early-to-mid 2030s. Regionally, North America maintained the largest market share in 2025, accounting for approximately 37% to 51% of global revenue, supported by strong venture capital funding, established biotechnology companies, advanced research infrastructure, and favorable regulatory frameworks. Meanwhile, the Asia-Pacific region is emerging as the fastest-growing market, driven by expanding healthcare infrastructure, increasing pharmaceutical and biotechnology research activities, and government initiatives promoting bio-manufacturing capabilities. From a technology perspective, gene synthesis and polymerase chain reaction (PCR) technologies represented the largest market segments in 2025, while genome engineering technologies, particularly CRISPR-based platforms, are witnessing the fastest growth due to their broad applications in genetic modification, therapeutic development, and industrial biotechnology. By product category, enzymes and oligonucleotides generated the highest revenue shares, reflecting their essential role in synthetic biology workflows. In terms of end users, biotechnology and pharmaceutical companies dominated the market, leveraging synthetic biology technologies for drug discovery, vaccine development, cell and gene therapies, and precision medicine applications. These factors collectively position synthetic biology as one of the most transformative and high-growth sectors within the global life sciences industry.

The global synthetic biology market is experiencing strong growth, driven by continuous advancements in gene editing technologies, DNA synthesis, genome engineering, and the increasing demand for sustainable bio-based products and personalized healthcare solutions. The market is estimated to be valued at approximately US$ 19–23 billion and is projected to exceed US$ 130 billion by 2035, expanding at a robust compound annual growth rate (CAGR) of approximately 18%–25% during the forecast period.

Healthcare and pharmaceutical applications currently account for the largest share of market revenue, representing more than 50% of the global market. This dominance is attributed to increasing investments in gene therapy, precision medicine, cell-based therapies, and scalable mRNA vaccine development. Within the product landscape, synthetic DNA, oligonucleotide pools, and other enabling biological tools continue to generate significant demand, while genome engineering technologies, particularly CRISPR-Cas9, are emerging as the fastest-growing technology segment due to their broad applicability in research, therapeutics, and industrial biotechnology.

From a regional perspective, North America maintains its leadership position in the synthetic biology market, supported by strong venture capital investments, government funding initiatives, advanced research infrastructure, and the presence of major biotechnology companies. Meanwhile, the Asia-Pacific region is witnessing the fastest growth, driven by expanding biotechnology ecosystems, increasing research activities, and growing investments in countries such as China, India, Singapore, and Japan.

Several transformative trends are shaping the future of the market. The integration of artificial intelligence (AI), machine learning, and bioinformatics into synthetic biology workflows is significantly improving the design-build-test-learn cycle, reducing development timelines and research costs while enhancing innovation efficiency. In addition, the global transition toward sustainable manufacturing and circular economy initiatives is accelerating the adoption of synthetic biology for the production of biodegradable plastics, biofuels, bio-based chemicals, and environmentally friendly surfactants. These advancements are positioning synthetic biology as a critical technology platform for addressing global challenges in healthcare, sustainability, agriculture, and industrial production.

Top market players in Synthetic biology market

Amyris Inc.

Amyris Inc. was founded in 2003 and headquartered in Emeryville, California, U.S. It is an industrial biotechnology company. The company is engaged in the engineering, production, and sales of a wide range of consumer and industrial markets, including cosmetics, flavors and fragrances, solvents and cleaners, polymers, lubricants, healthcare products, and fuels. The company manufactures renewable products which focus on fuels and chemicals that provide compromised sustainable options for a wide range of petroleum-sour products. It uses an industrial synthetic biology platform that converts plant sugars into hydrocarbon molecules and applies its new bioscience solutions to its specialty components and consumer products. Its technology produces products that support the discovery and production of biopharmaceutical drugs, from cosmetic emollients and fragrances to fuels, solvents, lubricants, and nutraceuticals. Amyris, Inc. is primarily in the business of industrial organic chemicals. It business operations are spread around the world, with most of the revenue generated in the United States. The company also earns from the sale of renewable products, intellectual property licenses, and royalties and grants, and collaborative research and development services. In addition, its biotechnology platform and industrial fermentation process replace the existing complex and expensive production process. The company’s platform is used to create, fabricate, optimize, and upscale strains on commercial volumes for more than 15 commercial components. Amyris uses a wide array of unique technologies, including state-of-the-art machine learning, robotics, and artificial intelligence. Its components are included in more than 3,000 products from the world's top brands, reaching more than 200 Billion customers. It has approximately 300 To 350 employees.

DuPont de Nemours, Inc.

It was formerly DowDuPont Inc., provides technology-based materials, ingredients and solutions. It is a non-family Business company that aims to have a leading role in to build a strong national economy. It is one of the leading companies manufacturing personal care products. The company operates through five business segment; electronics & imaging, nutrition & bioscience, transportation & industrial, safety & construction and non-core. DuPont de Nemours, Inc. commonly known as DuPont, it is an American company that was founded on August 31^st, 2017 by Dow Chemical & E. Income. Through the merger of Do Point Nemours and Company and subsequently Down Inc. Prior to Spin Off, it was the largest chemical company in the world in terms of sales. DuPont de Nemours, Inc. started out as a company that makes simple products. It offers products under various brands, such as Kevlar, Nomex, Tyvek, Sorona, Danisco, Corian, GREAT STUFF and Styrofoam. In addition, its products are sold worldwide. Most products are marketed primarily through the company's sales organization, the company has a diverse worldwide network which markets and distributes the company's brands to customers globally. This network consists of the company's sales and marketing organization partnering with distributors, independent retailers, cooperatives and agents throughout the world. It provides solutions to a range of markets, including automotive, building and construction, energy, government and public sector, military, law enforcement, emergency response, packaging and printing, and safety and protection industries. The company has subsidiaries in about 70 countries worldwide and manufacturing operations in about 40 countries. It has a headcount of approximately 98,000 employees.

New England Biolabs Inc.

New England Biolabs Inc. was founded in 1974 and is headquartered at Ipswich, Massachusetts, U.S. It is engaged in the discovery and development of restored and original enzymes for genomic research. New England Biolabs Inc. is one of the leading companies in the synthetic biology market. It offers restriction endonucleases for DNA digestion; PCR, polymerases, and amplification technologies for PCR applications; DNA modifying enzymes and cloning technologies; reagents for DNA and RNA sample preparation; DNA, RNA for electrophoresis for plexuses, and protein markers and ladders; reagents for RNA research; and gene expression tools for DNA, RNA and cell line protein transmission. The New England Biolab also offers cellular analysis solutions; antibodies, enzymes, reagents, and DNA controls for epigenetics research; protein expression and purification technologies; competent cells for transformation and protein expression protein tools, glycol biology products, and plasmids and DNAs for use in cloning experiments. The Company has over 450+ employees. It is a privately held company and has extensive worldwide distribution through a network of exclusive distributors, agents. It has seven subsidiaries located in China, France, Canada, Japan, Singapore, Germany, and the UK. And other regions also.

Genscript

Genscript Biotech Corporation is a global biotech company. GenScript was founded in 2002 and headquartered in New Jersey, U.S. by Dr. Fangliang (Frank) Zhang and was listed on the Hong Kong Stock Exchange in 2015. The Group is one of the leading life sciences research and application service and product providers that applies its proprietary technology to various fields from basic life sciences research to translational biomedical development, industrial synthetic products, and cell therapeutic solutions. There are more than 100 countries and territories in the genescript business worldwide that exist legally in the U.S., China, Hong Kong, China, Japan, Singapore, the Netherlands, and Ireland. The company provides products and services to 100,000 customers. As of June 30^th, 2020, GenScript has more than 3,900 employees globally. GenScript contains several intellectual property rights and trade secrets, with more than 140 patents and more than 450 pending patent applications.

Integrated DNA Technologies Inc.

Integrated DNA Technologies Inc.(IDT) was founded in 1987 and is headquartered in Coralville, IA, U.S. The company develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic research, biotechnology, agriculture, medical diagnostics, and pharmaceutical development. The company's primary business is the production of custom oligonucleotides for molecular biology applications. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, qPCR, and RNA interference. Through its GMP services, IDT manufactures products used in diagnostic tests for many forms of cancer and most inherited and infectious diseases. The company serves its customers through direct sales in many countries and a network of international distributors. IDT synthesizes and ships an average of 44,000 custom oligos per day to more than 82,000 customers worldwide. It has manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing facilities in San Diego, California, USA; Leuven, Belgium; and Singapore. Company serves more than 130,000 life sciences researchers in more than 100 countries and produces more than 90,000 nucleic acids daily. The company has a team of more than 14,000 professionals located in more than 100 countries which mainly focuses on nucleic acid products for the life sciences industry in the areas of academic research, biotechnology, agriculture, medical diagnostics, and pharmaceutical development.

Novozymes

Novozymes was founded in 2000 and is headquartered in Bagsvaerd, Denmark. It is one of the leading in bio innovation companies and producing a wide range of industrial enzymes and microorganism and biopharmaceutical ingredients. It is mainly engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company has wide geographical presence in Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. The company operates through a range of partnerships with companies, such as DONG Energy and Monsanto, Adisseo, Beta Renewables, and is a parent company of Novozymes Belgium BVBA, Albumedix A/S, Novozymes BioAg Limited, Novozymes Canada Limited, and Organobalance GmbH and others. The company offers its products and solutions have application the industries which are; household care, bioenergy, technical & pharma, food & beverages, and agriculture & feed. The company has a headcount of 6,125 employees working in its firm worldwide.

Koninklijke DSM N.V. 

The Royal DSM was founded in 1902 and is headquartered at Heerlen, the Netherlands. The Royal DSM is a science-based company engaged in the business of nutrition, health, and sustainable living in the Netherlands, the rest of Europe, North America, Latin America, China, India, Japan, the rest of Asia, and internationally. The company's segments include nutrition, performance materials, innovation center and corporate activities. The company has approximately 21,054 employees. The company has a wide geographical reach including; South Africa, Europe, North America, and others. In nutrition sector it offers animal nutrition and health products, including biotic, vitamins, lipids, enzymes, carotenoids, and minerals; Human nutrition and health products including carotenoids, digestive enzymes, nutritional lipids, nutraceuticals, probiotics and prebiotics and vitamins; and skin and sun care, hair care, and fragrance ingredients. It also provides vitamins and lipid active medicinal ingredients; Omega-3 fatty acids; Characteristic enzymes, cultures, probiotics, bio-preservation, sugar reduction, and juice solution; and specialty hydrocolloid solutions. The Royal DSM materials department provides thermoplastics used in automotive, building and construction, electrical and electronics, medical, food packaging, and consumer goods. The innovation center department provides biomedical materials and medical devices and materials manufacturing technologies, diabetes management, cardiovascular, dental, neurology, ophthalmology, gynecology, orthopedic, plastic, and reconstructive surgery, soft tissue and wound management. It also provides solar glass, retrofit AR and anti-soil coatings and anti-reflective (AR) coatings for carriers and PV back sheets; and yeasts and enzymes for the conversion of starch, corn fiber, and biomass. The Royal DSM has partnered with Strait Access Technologies to develop a trans-catheter replacement heart valve with polymeric sheets.

Precigen, Inc.

Precigen is a biotechnology company that develops synthetic biology solutions. The company designs, builds, and regulates gene programs. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The company is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in its core therapeutic areas of Immuno-oncology, autoimmune disorders, and infectious diseases. Its domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The company has disciplined design approach uses non-viral and viral expression systems, genome, DNA, RNA and protein engineering, and a suite of precision bioengineering switch technologies controlling gene expression and regulation to deliver potent on-target gene and cellular multifunctional therapies with improved safety and efficacy. Precigen, Inc. has approximately 600 employees and serves customers worldwide. Its technologies are broadly applicable across a wide range of diverse end markets. The Company's major technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; cell systems informatics; RheoSwitch inducible gene switch; AttSite recombinases; protein engineering; laser-enabled analysis and processing (LEAP), and ActoBiotics platform.